After spending about 14 billion euros ($16.4 billion) on acquisitions this year, Sanofi will look for purchases to bolster key therapeutic segments while refraining from megadeals such as bidding for Pfizer Inc.’s consumer business.
The drugmaker, which had a war chest of about 20 billion euros to spend on deals, will be “very disciplined” in its transactions by sticking to identified treatment areas such as oncology, rare diseases and diabetes, Chief Executive Officer Olivier Brandicourt said in an interview in Shanghai on Monday. “It gives us a little bit more room if there were bolt-on opportunities,” he said.
As generic ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.